0001816518-20-000001.txt : 20200701 0001816518-20-000001.hdr.sgml : 20200701 20200701130028 ACCESSION NUMBER: 0001816518-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200701 DATE AS OF CHANGE: 20200701 EFFECTIVENESS DATE: 20200701 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nine Square Therapeutics, Inc. CENTRAL INDEX KEY: 0001816518 IRS NUMBER: 850634503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-370079 FILM NUMBER: 201004803 BUSINESS ADDRESS: STREET 1: 230 PARK AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10169 BUSINESS PHONE: 781-367-5419 MAIL ADDRESS: STREET 1: 230 PARK AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10169 D 1 primary_doc.xml X0708 D LIVE 0001816518 Nine Square Therapeutics, Inc. 230 PARK AVENUE, SUITE 2800 NEW YORK NY NEW YORK 10169 781-367-5419 DELAWARE Waltz Therapeutics, Inc. None Corporation true 2020 Spiros Liras c/o Nine Square Therapeutics, Inc. 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Executive Officer Director Seth Harrison c/o Nine Square Therapeutics, Inc. 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Director Michael Ehlers c/o Nine Square Therapeutics, Inc. 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Director Matthew Jacobson c/o Nine Square Therapeutics, Inc. 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Director Biotechnology Decline to Disclose 06b false 2020-06-16 false true false 0 50000000 1000000 49000000 false 1 0 0 0 false Nine Square Therapeutics, Inc. /s/ Spiros Liras Spiros Liras Chief Executive Officer 2020-07-01